SAB Biotherapeutics Files 2024 10-K, Details Warrants
Ticker: SABSW · Form: 10-K · Filed: Mar 31, 2025 · CIK: 1833214
| Field | Detail |
|---|---|
| Company | Sab Biotherapeutics, Inc. (SABSW) |
| Form Type | 10-K |
| Filed Date | Mar 31, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, financial-instruments, biotech
TL;DR
SAB Bio 2024 10-K is in. Lots of warrant details, check Sanford Health deal.
AI Summary
SAB Biotherapeutics, Inc. filed its 2024 10-K on March 31, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Big Cypress Acquisition Corp., is focused on biological products. Key events and financial instruments mentioned include pipe warrants, preferred warrants, and Ladenburg agreements, with specific dates like March 21, 2023, and December 31, 2023, being relevant to these financial instruments.
Why It Matters
This filing provides investors with a comprehensive overview of SAB Biotherapeutics' financial health and operational status for the fiscal year 2024, including details on various financial instruments and agreements.
Risk Assessment
Risk Level: medium — The company's focus on biological products and the mention of various financial instruments like warrants suggest a potentially volatile and speculative business environment.
Key Numbers
- 2024 — Fiscal Year End (The period covered by the 10-K filing.)
- 2025-03-31 — Filing Date (The date the 10-K was submitted to the SEC.)
Key Players & Entities
- SAB Biotherapeutics, Inc. (company) — Filer of the 10-K
- Big Cypress Acquisition Corp. (company) — Former name of SAB Biotherapeutics, Inc.
- Sanford Health (company) — Mentioned in relation to a subsequent event (Lease Agreement)
- Ladenburg (company) — Associated with specific warrant agreements
- 2024-12-31 (date) — Fiscal year end for the reported 10-K
- 2025-03-31 (date) — Filing date of the 10-K
- 2023-03-21 (date) — Date related to Ladenburg Agreement Warrants
FAQ
What is the primary business of SAB Biotherapeutics, Inc.?
SAB Biotherapeutics, Inc. is primarily involved in biological products, as indicated by its SIC code [2836] and the company's focus.
When did SAB Biotherapeutics, Inc. change its name from Big Cypress Acquisition Corp.?
The date of the name change from Big Cypress Acquisition Corp. to SAB Biotherapeutics, Inc. was November 20, 2020.
What specific financial instruments are highlighted in the filing data?
The filing data highlights various financial instruments including pipe warrants, preferred warrants, Ladenburg Agreement Warrants, and Tranche B Warrants, with specific dates associated with them.
Is there any mention of subsequent events related to lease agreements?
Yes, a subsequent event related to a lease agreement with Sanford Health is mentioned, dated January 30, 2025.
What is the company's state of incorporation?
SAB Biotherapeutics, Inc. is incorporated in Delaware (DE).
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 31, 2025 regarding SAB Biotherapeutics, Inc. (SABSW).